DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Cisplatin + Gemcitabine
Drug: Cisplatin + Gemcitabine with SUBATM-itraconazole

First Posted Date: 2012-12-18

Last Posted Date: 2018-10-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT01752023

Locations: 🇺🇸
Bayview Medical Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University, SKCCC, Baltimore, Maryland, United States

Radiotherapy for Solid Tumor Spine Metastases

Phase 2

Completed

Conditions: Solid Tumor Spine Metastases

Interventions: Radiation: Post-operative, Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2012-12-18

Last Posted Date: 2020-06-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 35

Registration Number: NCT01752036

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Phase 2

Completed

Conditions: Recurrent Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2012-12-17

Last Posted Date: 2016-12-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 33

Registration Number: NCT01750398

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Screening for Lung Cancer in the HIV Patient

Completed

Conditions: HIV Seropositivity
Lung Cancer
Lung Cancer in the HIV Patient
HIV Infections

Interventions: Device: CT Scan with Spirometry

First Posted Date: 2012-12-12

Last Posted Date: 2019-03-28

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 200

Registration Number: NCT01748136

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Afatinib
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2012-11-26

Last Posted Date: 2018-07-26

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 9

Registration Number: NCT01732640

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States

Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide

Phase 1

Completed

Conditions: Newly Diagnosed High-Grade Glioma

Interventions: Drug: Mebendazole

First Posted Date: 2012-11-20

Last Posted Date: 2021-05-07

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 24

Registration Number: NCT01729260

Locations: 🇺🇸
The Johs Hopkins Hospital, Baltimore, Maryland, United States

Stereotactic Body Radiation With Nelfinavir for Oligometastases

Phase 2

Completed

Conditions: Oligometastases

Interventions: Drug: Nelfinavir
Radiation: Stereotactic Body Radiation (SBRT)

First Posted Date: 2012-11-20

Last Posted Date: 2021-07-12

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 38

Registration Number: NCT01728779

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

Phase 2

Completed

Conditions: Gastroesophageal Cancer
Gastric Cancer
Metastatic Esophageal Cancer

Interventions: Drug: Docetaxel
Drug: Leucovorin
Drug: Fluorouracil
Drug: Cisplatin

First Posted Date: 2012-10-26

Last Posted Date: 2019-03-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT01715233

Locations: 🇺🇸
SKCCC at Johns Hopkins, Baltimore, Maryland, United States

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Phase 1

Terminated

Conditions: Relapsed Acute Leukemia
Refractory Acute Leukemia
High-Risk Myelodysplasia

Interventions: Drug: PD 0332991

First Posted Date: 2012-10-05

Last Posted Date: 2013-09-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 2

Registration Number: NCT01701375

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Biological: Sargramostim

First Posted Date: 2012-10-04

Last Posted Date: 2022-10-18

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 25

Registration Number: NCT01700673

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy